- Home
- OLMA vs DAWN Comparison
OLMA vs DAWN Comparison
Compare OLMA & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OLMA
- DAWN
- Stock Information
- Founded
- OLMA 2006
- DAWN 2018
- Country
- OLMA United States
- DAWN United States
- Employees
- OLMA N/A
- DAWN N/A
- Industry
- OLMA Biotechnology: Pharmaceutical Preparations
- DAWN Biotechnology: Pharmaceutical Preparations
- Sector
- OLMA Health Care
- DAWN Health Care
- Exchange
- OLMA Nasdaq
- DAWN Nasdaq
- Market Cap
- OLMA 465.4M
- DAWN 1.3B
- IPO Year
- OLMA 2020
- DAWN 2021
- Fundamental
- Price
- OLMA $6.10
- DAWN $12.79
- Analyst Decision
- OLMA Strong Buy
- DAWN Strong Buy
- Analyst Count
- OLMA 5
- DAWN 7
- Target Price
- OLMA $26.25
- DAWN $36.17
- AVG Volume (30 Days)
- OLMA 1.2M
- DAWN 1.0M
- Earning Date
- OLMA 11-12-2024
- DAWN 10-30-2024
- Dividend Yield
- OLMA N/A
- DAWN N/A
- EPS Growth
- OLMA N/A
- DAWN N/A
- EPS
- OLMA N/A
- DAWN N/A
- Revenue
- OLMA N/A
- DAWN $101,953,000.00
- Revenue This Year
- OLMA N/A
- DAWN N/A
- Revenue Next Year
- OLMA N/A
- DAWN $36.10
- P/E Ratio
- OLMA N/A
- DAWN N/A
- Revenue Growth
- OLMA N/A
- DAWN N/A
- 52 Week Low
- OLMA $5.56
- DAWN $11.94
- 52 Week High
- OLMA $16.78
- DAWN $18.07
- Technical
- Relative Strength Index (RSI)
- OLMA 27.05
- DAWN 39.97
- Support Level
- OLMA $5.56
- DAWN $12.26
- Resistance Level
- OLMA $6.87
- DAWN $12.81
- Average True Range (ATR)
- OLMA 0.81
- DAWN 0.52
- MACD
- OLMA -0.28
- DAWN -0.05
- Stochastic Oscillator
- OLMA 10.12
- DAWN 28.94
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.